Corcept Therapeutics (CORT) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $78.08 -4.7%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.25, $0.10 better than the analyst estimate of $0.15. Revenue for the quarter came in at $117.7 million versus the consensus estimate of $109.6 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cirrus Logic, Inc. (CRUS) Tops Q2 EPS by 27c; offers guidance
- VivoPower posts $6.8M revenue and $0.6M profit in Q1 FY2027
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
